CD274 and neoplasm: In patients who received nivolumab, the similar hazard ratios for disease recurrence or death with tumor cell PD-L1 expression either below 1% or 1% or higher and the magnitude of benefit with respect to DFS were higher in those in whom nivolumab was given at 10 weeks or more following surgery compared to those in whom nivolumab was initiated less than 10 weeks after surgery.